Bob Lane emphasizes the importance of having a support system during prostate cancer diagnosis and treatment to help process information and provide emotional support. Lane's experience with cancer ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...

Prostate cancer develops in the prostate, a gland in the male reproductive system. When the cancer spreads to distant areas of the body, it is considered end-stage prostate cancer. There is no cure ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...